BioHarvest Sciences (NASDAQ:BHST) Price Target Cut to $8.00 by Analysts at Roth Capital

BioHarvest Sciences (NASDAQ:BHST) had its price objective decreased by stock analysts at Roth Capital from $10.00 to $8.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Roth Capital’s price target suggests a potential upside of 265.30% from the company’s current price.

Other equities research analysts also recently issued research reports about the company. Maxim Group set a $5.00 target price on BioHarvest Sciences in a research report on Wednesday. Weiss Ratings upgraded BioHarvest Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, June 18th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $6.50.

BioHarvest Sciences Stock Performance

NASDAQ:BHST traded up $0.11 during trading hours on Wednesday, reaching $2.19. The stock had a trading volume of 12,027 shares, compared to its average volume of 36,709. BioHarvest Sciences has a 12-month low of $1.82 and a 12-month high of $12.80. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.44 and a current ratio of 2.96. The stock has a 50 day simple moving average of $2.74 and a 200 day simple moving average of $3.80. The stock has a market cap of $42.97 million, a P/E ratio of -3.71 and a beta of 0.97.

BioHarvest Sciences (NASDAQ:BHST) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.04). The firm had revenue of $8.84 million during the quarter, compared to analysts’ expectations of $9.45 million. BioHarvest Sciences had a negative return on equity of 76.03% and a negative net margin of 32.54%. On average, research analysts forecast that BioHarvest Sciences will post -0.45 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of BHST. Alyeska Investment Group L.P. bought a new stake in BioHarvest Sciences during the 4th quarter valued at $3,929,000. Thompson Siegel & Walmsley LLC purchased a new position in shares of BioHarvest Sciences in the fourth quarter valued at about $1,945,000. Evercore Wealth Management LLC bought a new position in shares of BioHarvest Sciences during the fourth quarter valued at about $724,000. True North Advisors LLC boosted its holdings in shares of BioHarvest Sciences by 381.0% during the first quarter. True North Advisors LLC now owns 168,013 shares of the company’s stock worth $729,000 after purchasing an additional 133,085 shares during the period. Finally, King Luther Capital Management Corp purchased a new stake in shares of BioHarvest Sciences during the fourth quarter worth about $208,000.

BioHarvest Sciences News Roundup

Here are the key news stories impacting BioHarvest Sciences this week:

• Positive Sentiment: BioHarvest secured an exclusive manufacturing and supply agreement for up to 20 tons of a rare botanical fragrance ingredient through 2027 and 2028. The company estimates the deal could generate approximately $20 million to $30 million in revenue and supports its strategy of building a higher-margin contract development and manufacturing (CDMO) business. BioHarvest Secures 20-Ton Manufacturing and Supply Agreement for Rare Botanical Luxury Fragrance
• Positive Sentiment: Second-quarter revenue increased 3.8% year over year to about $8.8 million. Management said spending is being directed toward manufacturing capacity, including the planned commercial fragrance production program, which it expects to support a path toward profitable CDMO growth. BioHarvest posts higher Q2 revenue, secures manufacturing deal for premium fragrance compound
• Neutral Sentiment: Coverage of the earnings call and quarterly filing highlights the fragrance agreement, manufacturing expansion and broader botanical-synthesis strategy, but the new contract’s estimated revenue is largely scheduled for future years rather than the current quarter. BioHarvest Sciences Q2 2026 Earnings Call Transcript
• Neutral Sentiment: Reported short interest was zero shares as of August 11, offering no evidence of meaningful short-selling pressure or a short-squeeze catalyst.
• Negative Sentiment: BioHarvest reported a second-quarter loss of $0.17 per share, worse than the expected $0.13 loss, while revenue of $8.84 million fell short of the $9.45 million consensus estimate. Net margin and return on equity remained negative. BioHarvest Sciences Reports Q2 Loss, Lags Revenue Estimates
• Negative Sentiment: Fiscal 2026 revenue guidance of $37 million to $40 million is below the approximately $42.9 million analyst consensus, signaling that near-term growth may be slower than previously anticipated.

BioHarvest Sciences Company Profile

BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.

The company’s product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.